Endurance Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Endurance Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$22K	Hold	30	–	–	﹤0.01%	414
2023 Q1	$25K	Hold	30	–	–	﹤0.01%	419
2022 Q4	$22K	Hold	30	–	–	﹤0.01%	406
2022 Q3	$21K	Hold	30	–	–	﹤0.01%	404
2022 Q2	$18K	Hold	30	–	–	﹤0.01%	429
2022 Q1	$21K	Hold	30	–	–	﹤0.01%	439
2021 Q4	$19K	Hold	30	–	–	﹤0.01%	453
2021 Q3	$18K	Hold	30	–	–	﹤0.01%	466
2021 Q2	$16K	Sell	30 -2	-6%	-$1.01K	﹤0.01%	486
2021 Q1	$15K	Hold	32	–	–	﹤0.01%	493
2020 Q4	$15K	Sell	32 -18	-36%	-$9.72K	﹤0.01%	452
2020 Q3	$28K	Hold	50	–	–	﹤0.01%	362
2020 Q2	$31K	Buy	50 +18	+56%	+$10.2K	0.01%	359
2020 Q1	$16K	Buy	32 +2	+7%	+$825	﹤0.01%	384
2019 Q4	$11K	Hold	30	–	–	﹤0.01%	415
2019 Q3	$8K	Hold	30	–	–	﹤0.01%	435
2019 Q2	$9K	Hold	30	–	–	﹤0.01%	389
2019 Q1	$12K	Hold	30	–	–	﹤0.01%	376
2018 Q4	$11K	Hold	30	–	–	﹤0.01%	364
2018 Q3	$12K	Hold	30	–	–	﹤0.01%	392
2018 Q2	$10K	Hold	30	–	–	﹤0.01%	403
2018 Q1	$10K	Hold	30	–	–	﹤0.01%	429
2017 Q4	$11K	Hold	30	–	–	﹤0.01%	406
2017 Q3	$13K	Hold	30	–	–	﹤0.01%	386
2017 Q2	$15K	Hold	30	–	–	﹤0.01%	383
2017 Q1	$12K	Hold	30	–	–	﹤0.01%	394
2016 Q4	$11K	Hold	30	–	–	﹤0.01%	378
2016 Q3	$12K	Hold	30	–	–	﹤0.01%	383
2016 Q2	$10K	Hold	30	–	–	﹤0.01%	380
2016 Q1	$11K	Hold	30	–	–	﹤0.01%	384
2015 Q4	$16K	Hold	30	–	–	﹤0.01%	363
2015 Q3	$16K	Hold	30	–	–	﹤0.01%	359
2015 Q2	$15K	Buy	+30	New	+$14.6K	﹤0.01%	378

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Endurance Wealth Management's REGN Position: Q2 2023 in Review

Endurance Wealth Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2023 at 30 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #414.

Endurance Wealth Management first reported a position in REGN in Q2 2015 and has held it in 33 quarters since. The position peaked at $31K in Q2 2020. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

Endurance Wealth Management held 30 shares of Regeneron Pharmaceuticals worth $22K as of Q2 2023.
Endurance Wealth Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2023.
Regeneron Pharmaceuticals made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #414 holding.
Endurance Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 33 quarters since.
Endurance Wealth Management's Regeneron Pharmaceuticals position peaked at $31K in Q2 2020.
1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.